Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01369641 · ClinicalTrials.gov registry record · NA

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Terminated
Registry status
NA
Development phase
1
Enrollment target

NCT01369641 is a NA study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01369641, a NA study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

TERMINATED
Registry status
NA
Development phase
1 participants
Enrollment target

Study Summary

This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy. Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution which is used routinely as an otic solution delivered to the middle ear space. The hypothesis of this study is that local administration of sodium thiosulfate (STS) will result in improved hearing compared to ears not receiving the study drug in patients receiving systemic cisplatin therapy.

Interventions

  • DRUG Cisplatin
  • DRUG Sodium Thiosulfate (STS)
  • OTHER Saline (Placebo)
  • PROCEDURE Insertion of Pressure Equalization (PE) Tubes

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2011-08-24
Est. Completion 2013-05-02
Phase NA

What the Registry Record Tells You About NCT01369641

The ClinicalTrials.gov registry entry for NCT01369641 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.

NCT01369641 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01369641 about?

NCT01369641 is a clinical study titled "The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy". This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy. Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution which is used routinely as an...

What is the current status of trial NCT01369641?

This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2011-08-24. Estimated completion is 2013-05-02.

What interventions are being tested in trial NCT01369641?

The interventions under investigation include: Cisplatin (DRUG), Sodium Thiosulfate (STS) (DRUG), Saline (Placebo) (OTHER), Insertion of Pressure Equalization (PE) Tubes (PROCEDURE).

Who is sponsoring clinical trial NCT01369641?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.